InspireMD (NASDAQ: NSPR) Q1 2026 Earnings Preview: Analyst Expectations and Key Financials

• InspireMD is set to release its Q1 2026 financial results on May 4, 2026, with analysts projecting $2.70 million in revenue and an estimated -$0.19 EPS.
• The medical device company recently initiated a voluntary U.S. recall for its CGuard Prime 135 cm system due to performance issues, which may impact the upcoming financial report.
• Despite the recall, InspireMD reported a 53% increase in global unit sales and received FDA approval for its CGUARDIANS III study, while current financials show a strong current ratio of 5.74 but a negative P/E ratio of -1.73.

InspireMD, Inc. (NASDAQ: NSPR) is a medical device company that develops systems designed to prevent strokes. The company is scheduled to release its first-quarter financial results on May 4, 2026. This upcoming report will give investors a detailed look at the company's recent financial performance and operational activities.

Ahead of the announcement, Wall Street analysts have set their expectations for InspireMD's performance. They project the company will report revenue of $2.70 million. The forecast for earnings per share (EPS), which is the company's profit divided by its number of shares, is an estimated loss of -$0.19 per share.

Recent events may impact these financial results. As highlighted by GlobeNewswire, InspireMD initiated a voluntary U.S. recall for its CGuard Prime 135 cm system. The company took this step after the device's technical performance during a controlled launch did not meet the required standards for carotid artery procedures.

Despite this recall, the company reported strong clinical demand, with a 53% increase in global year-over-year unit sales. InspireMD also received FDA approval to start its CGUARDIANS III study for the SwitchGuard neuro protection system, marking progress in its product pipeline, as highlighted by GlobeNewswire.

Current financial data shows InspireMD has a Price-to-Sales ratio of 5.99. Its Price-to-Earnings (P/E) ratio is -1.73, which indicates the company is not currently profitable. However, InspireMD has a strong current ratio of 5.74, suggesting it has a solid ability to meet its short-term financial obligations.